Prospects for CV Risk Factor Reduction with PCSK9 and CEPT Inhibitor Therapies - A. Michael Lincoff, MD

↳ This is a section part of Moment: CRT 2016 Atherosclerosis & Research - Atherosclerosis & Lipid Management

Add this Moment to your Passport

Learn from this moment and keep it forever.

Add To Passport

$21.99

This moment is included in Simple Premium - Get started for free.

FREE with Simple Premium

Start your 30-day free trial

Simple Premium offers unlimited access to all premium moments. $30.00 per month. Cancel anytime.

Preview

Summary

Prospects for CV Risk Factor Reduction with PCSK9 and CEPT Inhibitor Therapies presented by A. Michael Lincoff, MD at CRT 2016

Add this Moment to your Passport

Learn from this moment and keep it forever.

Add To Passport

$21.99

This moment is included in Simple Premium - Get started for free.

FREE with Simple Premium

Start your 30-day free trial

Simple Premium offers unlimited access to all premium moments. $30.00 per month. Cancel anytime.

Target Audience

Interventional Cardiologists
Interventional Fellows
Physiology technicians
Nurses and other allied healthcare professionals
Imaging Specialists
Radiologists

Session Name: Atherosclerosis & Lipid Management

Track: Atherosclerosis & Research

Learning Objectives

The latest updates in Atherosclerosis & Research

Other Components in this Moment

Novel Therapies for Dyslipidemia - Michael Davidson, MD

Should We Target Triglycerides in Patients with Chronic Ischemic Heart Disease? - Allen Taylor, MD

Lipoprotein(a): Genes, Biological Role, Predictive Value and Drug Interventions - Evan Stein, MD, PhD

Update on HDL Infusions and Atherosclerosis Regression in the ACS Patient - H. Bryan Brewer, MD

What is the Role of Ezetimibe After IMPROV-IT? - Steven Nissen, MD

Prospects for CV Risk Factor Reduction with PCSK9 and CEPT Inhibitor Therapies - A. Michael Lincoff, MD

Are the PCSK9 Inhibitors the Panacea of Atherosclerosis Treatment: Effects on Lipid Lowering and Beyond - Evan Stein, MD, PhD

LDL Reduction by PCSK9 Inhibition - Steven Nissen, MD

Update on Clinical Trials with Novel CETP Inhibitors to Raise HDL: Where Are We Today? - H. Bryan Brewer, MD

Loading Simple Education